Although we're all hopeful that a sale eventually takes place and lets us move on with our money, this is probably the worst time to sell a small pharmaceutical. For one thing, small pharmaceuticals have been in a depression since 2022. And potential buyers are likely in wait-and-see mode while they measure the effects of RFK Jr. on the U.S. healthcare industry. We'll probably have a clearer picture in a year from now about those things as well as whether traction is being gained in new sales areas, including China. There's really not clear visibility now. If we sold now, we'd have to give away the farm.
Market Data 
Markets 
AI
